|
|
Article: The SIM2 Down's syndrome gene is a drug therapy target for solid tumors.
- Article from:
- Cancer Weekly
- Article date:
- June 10, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 JUN 10 - (NewsRx.com & NewsRx.net) -- The SIM2 Down's syndrome gene is a drug therapy target for solid tumors.
"We report here a cancer drug therapy use of a gene involved in Down's syndrome. Using bioinformatics approaches, we recently predicted Single Minded 2 gene (SIM2) from Down's syndrome critical region to be specific to certain solid tumors. Involvement of SIM2 in solid tumors has not previously been reported," scientists in the United States report.
"Intrigued by a possible association between a Down's syndrome gene and solid tumors, we monitored SIM2 expression in solid tumors. Isoform-specific expression of SIM2 short-form (SIM2-s) was ...